Advanced development of human mutant IDH1 inhibitors (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)

人类突变 IDH1 抑制剂的先进开发（化学生物学联盟/NCI 实验治疗合作组织）

• 批准号: 9358276
• 负责人: Matthew Boxer
• 金额: $ 22.7万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9358276
• 关键词: Advanced Development; Biology; Chemicals; Collaborations; Communities; Development; Disease; Disease model; Extramural Activities; Fostering; General Population; Genomics; Goals; Human; Informatics; Investigational Therapies; Lead; Modeling; Pharmaceutical Chemistry; Pharmaceutical Preparations; Process; Publications; Research; Research Personnel; Resources; Synthesis Chemistry; United States National Institutes of Health; Validation; Work; advanced disease; assay development; base; drug development; drug discovery; high throughput screening; human disease; improved; inhibitor/antagonist; mutant; new technology; novel; novel therapeutics; pre-clinical; screening; small molecule; small molecule therapeutics; therapeutic development; tool

This collaborative team - composed of groups from NCI, CBC/NExT, UNC and NCATS - aims to build on previous research by uncovering novel inhibitors of mutant IDH1 for anticancer indications. As a center, the NCGC has fostered and maintained over 110 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.

这个合作团队由来自 NCI、CBC/NExT、UNC 和 NCATS 的小组组成，旨在以先前的研究为基础，发现用于抗癌适应症的突变 IDH1 的新型抑制剂。 作为一个中心，NCGC 与 NIH 和校外研究人员建立并维持了 110 多项积极合作，促进了整个人类疾病范围的药物发现工作。 这些努力导致了数十次高通量筛选和许多药物化学活动，以进一步提高筛选命中率，为我们的合作者和一般研究界提供出版物和各种有前途的小分子探针和先导化合物。 此外，NCGC还致力于推进多项信息化举措，以更好地利用现有药物和疾病靶点信息，为公众提供易于获取的资源，进一步促进人类疾病新疗法的开发。